Responses
Original research
Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
Compose a Response to This Article
Other responses
No responses have been published for this article.